EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration

Alberto Benussi iD, Hanna Huber, Kübra Tan, Valentina Cantoni, Jasmine Rivolta, Maria Sofia Cotelli, Andrea L Benedet, Kaj Blennow, Henrik Zetterberg, Nicholas J Ashton, Barbara Borroni

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Alberto Benussi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Frontotemporal Lobar Degeneration, Neurofilament Proteins. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AD Strategic Fund and the Alzheimer's Association, Swedish Research Council, Bluefield Project, Cure Alzheimer's Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Plasma‐based biomarkers have shown promise for clinical implementation, but their accuracy in differentiating Alzheimer's disease (AD) from syndromes associated with frontotemporal lobar degeneration (FTLD) has yet to be fully investigated. This study assessed the potential of plasma biomarkers for differential diagnosis. METHODS This cohort study included 374 participants (96 AD, 278 FTLD). Plasma phosphorylated tau (p‐tau) 217 , neurofilament light chain (NfL), brain‐derived tau, glial fibrillary acidic protein, and the amyloid beta 1‐42 / 1‐40 ratio were measured. Receiver operating characteristic curve analyses assessed diagnostic accuracy, and a three‐range threshold approach was used to stratify patients based on the most accurate biomarker. RESULTS Plasma p‐tau 217 effectively distinguished AD from FTLD, with the NfL/p‐tau 217 ratio showing superior accuracy. The three‐range approach identified thresholds with 95% and 97.5% sensitivity and specificity, reducing the need for cerebrospinal fluid testing by 75% and 54%, respectively. DISCUSSION Plasma p‐tau 217 and the NfL/p‐tau 217 ratio are promising non‐invasive biomarkers for differentiating AD from FTLD, suggesting their use as a potential alternative to traditional diagnostic methods. Highlights Plasma phosphorylated tau (p‐tau) 217 distinguishes Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD) with high accuracy. The neurofilament light chain/p‐tau 217 ratio showed the highest accuracy for differentiating AD from FTLD. A three‐range threshold reduces the need for invasive cerebrospinal fluid testing or amyloid positron emission tomography imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseFrontotemporal Lobar DegenerationNeurofilament ProteinsHumansFemaleMaleDiagnosis, DifferentialBiomarkersAgedCohort StudiesMiddle AgedPhosphorylationAmyloid beta-PeptidesAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's diseaseblood‐based biomarkersdiagnostic accuracyfrontotemporal lobar degenerationneurofilament light chainphosphorylated tau217

Substanzen

tau ProteinsBiomarkersNeurofilament Proteinsneurofilament protein LAmyloid beta-Peptides

Autor:innen und Institutionen

  • Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska, Academy, University of Gothenburg, Gothenburg, Sweden.
  • Cognitive and Behavioural Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili di Brescia, Brescia, Italy.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
  • Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated…

ORCID-Profile: Alberto Benussi

Förderung

  • AD Strategic Fund and the Alzheimer's Association
  • Swedish Research Council
  • Bluefield Project, Cure Alzheimer's Fund
  • Olav Thon Foundation
  • Swedish Alzheimer Foundation
  • Fondation pour la Recherche sur Alzheimer
  • the Marie Skłodowska-Curie
  • NEuroBioStand

Zitieren

APA

Benussi, A., Huber, H., Tan, K., Cantoni, V., Rivolta, J., Cotelli, M. S., Benedet, A. L., Blennow, K., Zetterberg, H., Ashton, N. J., & Borroni, B. (2025). Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14482

Vancouver

Benussi A, Huber H, Tan K, Cantoni V, Rivolta J, Cotelli MS, et al. Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14482

BibTeX
@article{Benussi2025,
  author = {Benussi, Alberto and Huber, Hanna and Tan, Kübra and Cantoni, Valentina and Rivolta, Jasmine and Cotelli, Maria Sofia and Benedet, Andrea L and Blennow, Kaj and Zetterberg, Henrik and Ashton, Nicholas J and Borroni, Barbara},
  title = {Plasma p‐tau 217 and neurofilament/p‐tau 217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14482}
}
Kostenlos starten →